Stay updated on Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial page.

Latest updates to the Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3; no substantive study content changes are evident.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedRevision: v3.4.2 was added, and a notice about government funding was removed along with Revision: v3.4.1. These are administrative updates that do not affect study details or outcomes.SummaryDifference0.5%

- Check38 days agoChange DetectedA site-wide government funding notice banner was added and the revision tag was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check45 days agoChange DetectedAdded a glossary toggle in the header and introduced metadata labels 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' with revision updated to v3.4.0. Removed the older labels 'Last Update Submitted that met QC Criteria' (lowercase 'met'), 'No FEAR Act data', and the previous revision note v3.3.4.SummaryDifference0.2%

- Check81 days agoChange DetectedFooter now displays Revision: v3.3.3. The HHS Vulnerability Disclosure link and the Revision: v3.3.2 entry were removed.SummaryDifference0.1%

- Check103 days agoChange DetectedThe page revision label updated from v3.3.1 to v3.3.2. No substantive study information appears to be changed.SummaryDifference0.1%

Stay in the know with updates to Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial page.